Repository Citation
Wiedemer, Joseph; Espenschied, Jennifer; McKoy, Trevor; Schmeusser, Benjamin; Drozd, Andrew; Bierly, Jeffrey; and Yu, Michael, "Efficacy of UroLift Procedure for BPH by a Single Center of Excellence over 5 years" (2021). Medical Student Research Symposium Abstracts and Posters. 4.
https://corescholar.libraries.wright.edu/msrs/2021/poster_presentations_2/4
Start Date
29-4-2021 7:35 PM
End Date
29-4-2021 7:45 PM
Document Type
Poster
Description
Since receiving FDA approval in 2013, the Urolift intervention for BPH has shown to be a promising alternative to the TURP characterized by nearly equal efficacy with markedly reduced recovery time. The 5-year L.I.F.T study is by far the most robust Urolift research published to-date, which reports on a prospective randomized controlled study of 206 subjects. The L.I.F.T study reported stable improvement in the vast majority of patients over 5 years including preserved uroflow improvement from initial post-op evaluation and just 13.6% requiring surgical retreatment. Despite the procedure’s ostensibly high efficacy, more research is needed on a larger scale.
Urologists who have received a high level of training on the procedure are designated as a “Center of Excellence” (COE). COE physicians must meet several benchmarks to be given this designation, which includes the completion of 60 Urolift cases within a 12-month period.5 COE physicians must also submit data from a minimum of 30 cases showing a 40% average improvement in post-op IPSS from pre-op baseline. A comprehensive review of the literature yielded just one article single center/single surgeon experience with Urolift performed on just 11 patients.1 Our group aimed to evaluate the efficacy of Urolift from a single-surgeon designated as Center of Excellence over a 5-year period.
Abstract - Espenschied
Included in
Efficacy of UroLift Procedure for BPH by a Single Center of Excellence over 5 years
Since receiving FDA approval in 2013, the Urolift intervention for BPH has shown to be a promising alternative to the TURP characterized by nearly equal efficacy with markedly reduced recovery time. The 5-year L.I.F.T study is by far the most robust Urolift research published to-date, which reports on a prospective randomized controlled study of 206 subjects. The L.I.F.T study reported stable improvement in the vast majority of patients over 5 years including preserved uroflow improvement from initial post-op evaluation and just 13.6% requiring surgical retreatment. Despite the procedure’s ostensibly high efficacy, more research is needed on a larger scale.
Urologists who have received a high level of training on the procedure are designated as a “Center of Excellence” (COE). COE physicians must meet several benchmarks to be given this designation, which includes the completion of 60 Urolift cases within a 12-month period.5 COE physicians must also submit data from a minimum of 30 cases showing a 40% average improvement in post-op IPSS from pre-op baseline. A comprehensive review of the literature yielded just one article single center/single surgeon experience with Urolift performed on just 11 patients.1 Our group aimed to evaluate the efficacy of Urolift from a single-surgeon designated as Center of Excellence over a 5-year period.
